AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (NASDAQ:AZN) shares gained in European trading on Thursday after the Anglo-Swedish drugmaker reported better-than-expected Q4 2024 results and addressed investor concerns over an ...
businesslive.co.za44m
AstraZeneca flags possible $4.5m Chinese tax fine
A fine of between one and five times the unpaid tax of $900,000 could be levied if the company is found liable ...